AtriCure, Inc. (NASDAQ:ATRC) Stock Holdings Lessened by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lowered its stake in AtriCure, Inc. (NASDAQ:ATRC) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 181,722 shares of the medical device company’s stock after selling 4,097 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.37% of AtriCure worth $5,553,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Heck Capital Advisors LLC acquired a new stake in AtriCure during the 4th quarter valued at $60,000. Venturi Wealth Management LLC grew its holdings in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock valued at $69,000 after acquiring an additional 2,100 shares in the last quarter. KBC Group NV grew its holdings in shares of AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after acquiring an additional 932 shares in the last quarter. R Squared Ltd purchased a new position in shares of AtriCure during the 4th quarter valued at $89,000. Finally, AlphaQuest LLC grew its holdings in shares of AtriCure by 855.1% during the 4th quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company’s stock valued at $155,000 after acquiring an additional 4,532 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on ATRC shares. Canaccord Genuity Group boosted their price target on shares of AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on shares of AtriCure from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Oppenheimer upped their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Piper Sandler upped their price objective on shares of AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $51.56.

AtriCure Stock Up 1.7 %

AtriCure stock opened at $33.31 on Monday. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -35.06 and a beta of 1.53. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The firm has a fifty day moving average price of $38.10 and a two-hundred day moving average price of $33.48.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 6,100 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now owns 17,828 shares of the company’s stock, valued at $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.20% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.